Apollo Therapeutics

Apollo Therapeutics is a biopharmaceutical company, rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. We identify and develop pre-clinical and clinical stage assets with strong biological hypotheses and the potential to become meaningful new treatment options. Our team combines ‘drug hunters’ and deep subject matter experts who together are building an expansive and de-risked portfolio in oncology, major inflammatory disorders, and rare diseases. Backed by leading specialist investors including Patient Square Capital and Rock Springs Capital, we have operations in Cambridge, UK, and Boston, USA. Apollo Therapeutics has core innovation sourcing and drug discovery collaborations with four of the world’s leading universities; University of Cambridge, University College London, Imperial College London, and Kings College London.